Tradestie Institutional Equity Comparison Engine

CGON vs EDIT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Momentum & Technical, Options & Structure while EDIT counters with relative strength in Growth & Margin. Fundamentally, CGON trades at N/M Forward P/E with -4293.5% operating margin (-3.7% YoY revenue) versus EDIT at N/M Forward P/E and -167.0% operating margin (+37.4% YoY). In options structure, CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro) against EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CGON N/M vs EDIT N/M Fwd P/E
Growth & Margin Winner EDIT
Op Margin -4293.5% vs -167.0% ยท YoY -3.7% vs +37.4%
Momentum & Technical Winner CGON
1Y +125.0% vs -25.0% ยท 52W Pos 84% vs 11%
Options & Structure Winner CGON
CONSOLIDATION (85th %ile IV) vs BREAKDOWN (38th %ile IV)
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
1M Return +41.93%
1Y Return +124.96%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
48.4 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGON +124.96% EDIT -25.0% Spread: +149.96 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CGON Revenue EDIT Revenue CGON Op. Margin EDIT Op. Margin Margin Edge
FY2018 N/A $30M N/A -356.1% EDIT
FY2019 N/A $20M N/A -686.4% EDIT
FY2020 N/A $90M N/A -148.6% EDIT
FY2021 N/A $30M N/A -756.1% EDIT
FY2022 N/A $20M N/A -1146.3% EDIT
FY2023 $0M $80M -27180.9% -216.6% EDIT
FY2024 $0M $30M -10067.3% -777.2% EDIT
FY2025 $0M $40M -4722.1% -394.9% EDIT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGON (5) vs EDIT (3)
Institutional Metric CGON EDIT Criterion Row Winner
Market Capitalization Scale $6.3B $336.5M Larger Scale CGON
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -3.7% +37.4% Higher Growth EDIT
Operating Margin (TTM) Profitability -4293.5% -167.0% Higher Margin EDIT
Net Profit Margin Profitability 0.0% -144.9% Higher Margin CGON
Return on Equity (ROE) Capital Efficiency -28.3% -147.4% Higher ROE CGON
52-Week Range Position Momentum 84% ($37โ€“$94) 11% ($2โ€“$4) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 0.75ฮฒ ยท 89% Vol 2.32ฮฒ ยท 102% Vol Lower Realized Risk CGON
Unified Institutional Score Composite Signal 45.0 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite EDIT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGON vs EDIT Buy Guide
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGON nor EDIT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.